BofA analyst Travis Steed notes that the risk of instrument reprocessing recently came more of a focus for Intuitive Surgical (ISRG) investors after Restore Robotics got 510(k) clearance for reprocessed Da Vinci Xi Monopolar Scissors in March and and announced its first in human case to close out May. While the firm acknowledges this as “a risk worth monitoring,” it does not see this as “a thesis changing risk” and thinks reprocessed instruments will face a slow adoption so it does not see a near term impact. The firm, which sees Intuitive Surgical estimates moving higher in the near term and driving the stock higher, maintains its Buy rating and $650 price target on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical’s Growth Potential Outweighs Reprocessing Risks: Buy Rating Maintained
- Barclays says pullback ‘attractive’ buying opportunity for Intuitive Surgical
- Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
- Tesla, Intuitive Surgical downgraded: Wall Street’s top analyst calls
- Deutsche downgrades Intuitive Surgical to Sell on I&A segment risk
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue